Q1 2024 financial results

03 May 2024

Galápagos

Disclaimer

This presentation contains “forward-looking statements”, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “anticipate,” “believe,” “expect”, “next,” “ seek,” “upcoming,” “future,” “estimate,” encouraging,” “aim,” “can,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “intend,” “may,” “might,” “plan,” “potential,” “will,” “towards,” “continue,” “should”, “progress,” “remain,” “explore,” “further” “call to action,” and “predict,” or similar expressions. These statements include, but are not limited to: the guidance from management regarding our financial results, and expected operational use of, cash, statements regarding our strategic and capital allocation priorities, statements regarding our regulatory outlook, business strategy and statements regarding preliminary, interim and topline data from our preclinical and clinical studies and any other data or analyses related to programs, and our plans and strategy with respect to such studies, statements about our ability to advance product candidates into and successfully complete, clinical trials, statements regarding the timing and likelihood of business development projects and external innovation, statements regarding the amount and timing of potential future milestones, opt-in, royalty or other payments, statements regarding our R&D plans, strategy and outlook, including progress on our oncology or immunology portfolio and our CAR-T portfolio, including any potential changes in such strategy, statements regarding our pipeline and complementary technology platforms facilitating future growth, statements regarding our commercialization efforts for our product candidates and any of our future approved products, if any, statements regarding the potential attributes and benefits of our product candidates, including indications, dosing and treatment modalities, and their potential competitive position with respect to the other treatment alternatives, statements regarding the global R&D collaboration with Gilead, and the amendment of our arrangement with Gilead for commercialization and development of filgotinib, statements relating to the development of our commercial organization, and rollout of product candidates (if approved) globally, statements relating to the development of our distributed manufacturing capabilities on a global basis, statements regarding our supply chain, including our reliance on third parties, and statements regarding our sustainability plans. We caution the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of any future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause our actual results, financial condition and liquidity, performance or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such statements. In addition, even if Galapagos’ results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, the risk that our beliefs, management’s guidance, and expectations regarding our 2024 cash burn, operational expenses, or other financial metrics may be incorrect (including because one or more of our assumptions underlying our revenue or expense expectations may not be realized), the risk that ongoing and future clinical trials may not be completed in the currently envisaged timelines or at all, the inherent risks and uncertainties associated with competitive developments, clinical trials, recruitment of patients, estimated patient populations, product development activities and regulatory approval requirements (including, but not limited to, the risk that data and timing from our ongoing and planned clinical research programs may not support registration or further development of our product candidates due to safety, or efficacy concerns, or any other reasons), risks related to the potential benefits and risks related to our current collaborations, including our plans and ability to enter into collaborations for additional programs or product candidates, risks related to the acquisitions of CellPoint and AboundBio, including the risk that we may not achieve the anticipated benefits of the acquisitions of CellPoint and AboundBio, the inherent risks and uncertainties associated with target discovery and validation, and drug discovery and development activities, the risk that the preliminary and topline data from our preclinical and clinical studies may not be reflective of the final data, risks related to our reliance on collaborations with third parties (including, but not limited to, Gilead, BridGene Biosciences and Thermo Fisher), the risk that we will not be able to continue to execute on our currently contemplated business plan and/or will revise our business plan, including the risk that our plans with respect to CAR-T may not be achieved on the currently anticipated timeline or at all, the risk that our projections and expectations regarding the commercial potential of our product candidates or expectations regarding the revenues and costs associated with the commercialization rights may be inaccurate, risks related to the transaction between Galapagos and Alfasigma, the risks related to our strategic transformation exercise, including the risk that we may not achieve the anticipated benefits of such exercise on the currently envisaged timeline or at all. A further list and description of these risks, uncertainties and other risks can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on any such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date hereof. We expressly disclaim any obligation to update any such forward-looking statements herein to reflect any change in our expectations with regard thereto, or any change in events, conditions or circumstances,, unless specifically required by law or regulation. Under no circumstances may any copy of this presentation, if obtained, by retained, copied or transmitted.

Agenda

1	Driving value creation	Dr. Paul Stoffels*, CEO
2	Operational, financial update & outlook	Thad Huston, CFO & COO
3	Q&A	All

*Throughout this presentation, ‘Dr. Paul Stoffels’ should be read as ‘Dr. Paul Stoffels, acting via Stoffels IMC BV’

Galápagos

OUR VISION

To **transform patient outcomes** through **life-changing science** and **innovation** for more **years** of life and **quality** of life around the globe.

OUR MISSION

We **accelerate** transformational **innovation** through the relentless pursuit of **ground-breaking science**, our **entrepreneurial** spirit and a **collaborative** mindset.

Driving value creation

Despite advances in oncology and immunology, significant unmet patient needs remain

- Focused on indications with breakthrough designation potential to address high unmet patient needs in oncology and immunology
- Broad R&D pipeline of potential best-in-class cell therapies and small molecule drugs
- Strong leadership with track record of delivering transformative drugs
- Collaborative approach, combining internal and external innovation
- Strong cash position of €3.6 billion as of 31 March 2024

Experienced team – strong global leadership

Key capabilities in place to deliver value

Paul Stoffels*
CEO and Chairman
J&J, Tibotec, Virco

Philippe Alen
Head Business Development
Bayer, J&J, Virco

Valeria Cnossen*
General Counsel
J&J, Crucell

Dirk de Naeyer
Head Development Operations
Kiadis, J&J

Robert Hughes
Global Head of Technical Operations
Miltenyi, Siegfried

Thad Huston*
CFO/COO
Kite, LivaNova, J&J

Annelies Missotten*
Chief HR Officer
GSK

John Mellors
Head Cell & Antibody Therapy Discovery
AboundBio, UPMC Pittsburgh

Guy Peeters
SVP Finance
J&J

Pierre Raboisson
Head Small Molecules Discovery
Aligos, J&J, Tibotec

Patrik Ringblom
Head of Strategy & US Lead
J&J

Jake Treese
Global Head of Quality
BMS, AstraZeneca, GSK, Merck & Co

Galápagos

***Executive Officers**

Building on differentiated platform technologies

For greater patient impact across the globe

Cell Therapy

We have an innovative, scalable decentralized manufacturing platform to deliver fresh CAR-T therapies close to patients

Small Molecules

We are complementing our end-to-end R&D experience in small molecules with platform innovation



Biologics

We have a unique engine to discover and develop armed, multi-targeting CAR-Ts for heme-onc and solid tumors

Broadening our pipeline

Aim to deliver best-in-class therapeutics in oncology and immunology

ONCOLOGY

PROGRAM	TARGET	INDICATION	MODALITY	PRECLINICAL	PHASE 1	PHASE 2
5101	CD19	rrNHL	CAR-T			
5201	CD19	rrCLL/RT	CAR-T			
5301	BCMA	rrMM	CAR-T			
>5 programs	Multiple	Heme-onc & solid tumors	CAR-T			
>5 programs	Multiple	Solid tumors	Small molecule			

IMMUNOLOGY

PROGRAM	TARGET	INDICATION	MODALITY	PRECLINICAL	PHASE 1	PHASE 2
3667	TYK2	SLE	Small molecule			
3667	TYK2	DM	Small molecule			
>5 programs	Multiple	Inflammation/auto-immune	Small molecule			

CLL, chronic lymphocytic leukemia; DM, dermatomyositis; FIH, first-in-human clinical studies; Heme-onc, hematological oncology; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; rr, relapsed/refractory; SLE, systemic lupus erythematosus

Galápagos

Automated end-to-end system for decentralized CAR-T manufacturing

Aim to address the limitations of existing CAR-T therapies



Capacity constraints I Cryopreserved cells
Complex logistics I Limited global access

Galápagos

Delivering fresh, fit cells in 7 days vein-to-vein

Aim to address the limitations of existing CAR-T therapies



Fresh cells, 7 days vein-to-vein
Scalable globally I Near the patient

Galápagos

Expanding our decentralized CAR-T network

Accelerate US footprint

- Landmark Bio (Boston), Thermo Fisher (SF)
- Adding additional sites
- Expanded U.S. footprint

Expand EU network

- Active in 3 countries (Belgium, the Netherlands, Spain) with 5 clinical centers
- Further expanding our reach with additional PMUs



Progressing rejuvenated Discovery portfolio

Building on innovative biologics discovery and expertise in small molecules

IMMUNOLOGY	ONCOLOGY
Cell therapy	
• Exploring differentiated cell therapy strategies for B-cell depletion	• >5 programs across heme & solid cancers • Multiple differentiated armoring strategies to enhance CAR-T performance & durability
Small molecules	
• >5 programs across indications identified • Different stages of preclinical development	• >5 programs across cancer types identified • Deliver precision medicines

Key financials 1Q24

Millions of €	1Q24	1Q23	% change
Total net revenues	**62.4**	**58.6**	**+7%**
Cost of sales	(2.5)	-	
R&D	(71.6)	(52.5)	+36%
G&A, S&M	(30.8)	(27.1)	+14%
Other operating income	9.4	6.8	+37%
Operating loss	**(33.1)**	**(14.2)**	
FV adjustments and net exchange differences	30.6	(9.7)	
Net financial result	25.4	12.5	
Income taxes	0.6	0.2	
Net profit/loss from continuing operations	**23.5**	**(11.2)**	
Net profit/loss discontinued operations	66.7	34.4	
Net profit/loss	**90.2**	**23.2**	

FV, fair value

1Q24 revenues flat YoY

- €57.6M revenue recognition for platform

Investing in oncology TA

- Increase in R&D (+36%) YoY mainly driven by expansion in oncology in both CAR-T & small molecules

Net profit gain driven by

- €30.6M fair value adjustments and currency exchange gains
- €25.2M interest income
- Net profit of €66.7M from discontinued operations including a €53M gain of one day for the Alfasigma transaction

Galápagos

Strong balance sheet & streamlined operations

Disciplined spending to maximize value creation

€280-320M

2024 cash burn guidance
Reconfirmed

Excludes potential BD

~ €3.6B

Cash position*

Drive next stage of growth to support R&D and collaboration opportunities

*as of end of March 2024
Guidance based on current Galapagos estimates

Galápagos

Outlook 2024

Regulatory progress

- IND submission ‘5101 CD19 CAR-T in rrNHL
- IND submission ‘5201 CD19 CAR-T in rrCLL and RT

Program updates

- Update Ph1/2 ‘5101 CD19 CAR-T in rrNHL (ATALANTA)
- Update Ph1/2 ‘5201 CD19 CAR-T in rrCLL and RT (EUPLAGIA)
- Update Ph1/2 ‘5301 BCMA CAR-T in rrMM (PAPILIO)

Operational progress & BD

- Expand decentralized CAR-T network
- License agreements and/or acquisitions
- Research collaborations & equity investments

Building a global innovative biotech

Strong fundamentals in place

Progress early-stage pipeline

Leverage differentiated platforms & portfolio

Broaden product portfolio

Execute on BD opportunities

Deliver on scientific progress

Advance trials in immunology & oncology

Strengthen capabilities

Build world-class global team

Strong cash balance

Disciplined spending to maximize value creation

Q&A

#PioneeringForPatients

Follow us @GalapagosNV | GLPG.com

Galápagos